Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

  1. Budde, L.E.
  2. Sehn, L.H.
  3. Matasar, M.
  4. Schuster, S.J.
  5. Assouline, S.
  6. Giri, P.
  7. Kuruvilla, J.
  8. Canales, M.
  9. Dietrich, S.
  10. Fay, K.
  11. Ku, M.
  12. Nastoupil, L.
  13. Cheah, C.Y.
  14. Wei, M.C.
  15. Yin, S.
  16. Li, C.-C.
  17. Huang, H.
  18. Kwan, A.
  19. Penuel, E.
  20. Bartlett, N.L.
Aldizkaria:
The Lancet Oncology

ISSN: 1474-5488 1470-2045

Argitalpen urtea: 2022

Alea: 23

Zenbakia: 8

Orrialdeak: 1055-1065

Mota: Artikulua

DOI: 10.1016/S1470-2045(22)00335-7 GOOGLE SCHOLAR

Garapen Iraunkorreko Helburuak